Biocryst Pharmaceuticals (BCRX) Accounts Payables (2010 - 2026)

Biocryst Pharmaceuticals has reported Accounts Payables for 17 years, with the latest figure at $11.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 9.05% year-over-year to $11.0 million; the trailing twelve-month figure through Mar 2026 stood at $11.0 million (up 9.05% YoY), and the FY2025 full-year result was $15.8 million, up 35.92% from the prior year.
• Accounts Payables for Q1 2026 stood at $11.0 million, down from $15.8 million in the prior quarter.
• The five-year high for Accounts Payables was $20.9 million in Q4 2023, with the low at $5.6 million in Q3 2025.
• Historically, Accounts Payables has averaged $11.5 million across 5 years, with a median of $11.6 million in 2024.
• Annual changes were most pronounced in 2024 — Accounts Payables jumped 90.44% — and 2025, when it sank 58.71%.
• Biocryst Pharmaceuticals' Accounts Payables stood at $14.4 million in 2022, then soared by 45.53% to $20.9 million in 2023, then plunged by 44.27% to $11.6 million in 2024, then jumped by 35.92% to $15.8 million in 2025, then tumbled by 30.76% to $11.0 million in 2026.
• The last three Accounts Payables figures came in at $11.0 million (Q1 2026), $15.8 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.